* Cellectar Biosciences Inc reported a quarterly adjusted loss of 74 cents per share for the quarter ended in March, higher than the same quarter last year, when the company reported EPS of -76 cents. The mean expectation of three analysts for the quarter was for a loss of 56 cents per share. Wall Street expected results to range from -69 cents to -47 cents per share.
* Reported revenue was zero; analysts expected zero.
* Cellectar Biosciences Inc's reported EPS for the quarter was a loss of 74 cents.
* The company reported a quarterly loss of $21.58 million.
* Cellectar Biosciences Inc shares had fallen by 23.1% this quarter and gained 10.5% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 6.3% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the pharmaceuticals peer group is "buy."
Wall Street's median 12-month price target for Cellectar Biosciences Inc is $12.50 This summary was machine generated from LSEG data May 14 at 01:52 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.56 -0.74 Missed
Dec. 31 2023 -0.57 -0.61 Missed
Sep. 30 2023 -0.52 -0.83 Missed
Jun. 30 2023 -0.64 -0.73 Missed
Comments